Figure 3.

Antitumor activity of FL118 in individual mice with daily x 5 schedules in human FaDu head-&-neck tumors (A-C) or SW620 colon (D-F) tumors in SCID mouse xenograft models: Tumor models were established as described in the Methods. Treatment was initiated 7 days after subcutaneous tumor implantation (designated day 0), on which tumor size was about 200 - 250 mm³. FL118 in the Tween 80-free i.v. formulation was administrated via i.v. routes on day 0 at the doses and schedules shown. A and D. Control group was treated with the control solution without FL118 daily for 5 times (daily x 5). B and E. Antitumor activity of FL118 at the dose of 1.5 mg/kg with daily x 5 schedules. C and F. Antitumor activity of FL118 at the dose of 2.5 mg/kg with daily x 5 schedules.